MedElevator
Войти в исследования European journal of gastroenterology & hepatology · 2026
Clostridioides difficile infection increases the need for using biologics in patients with inflammatory bowel diseases: a retrospective long-term study.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Spagnuolo Rocco, Scarlata Giuseppe Guido Maria, Morano Domenico, Imoletti Felice, Marascio Nadia, Pantanella Marta, Suraci Evelina, Marasco Raffaella, Imeneo Maria, Serapide Francesca, Trecarichi Enrico Maria, Russo Alessandro, Quirino Angela, Abenavoli Ludovico, Matera Giovanni, Luzza Francesco
Аннотация
BACKGROUND: Inflammatory bowel disease (IBD), comprising Crohn's disease and ulcerative colitis, is characterized by chronic intestinal inflammation and may be complicated by gastrointestinal infections. Among these, Clostridioides difficile infection (CDI) is relevant because of its association with worse outcomes and increased therapeutic needs. We aimed to evaluate the prevalence of enteric infections during IBD flares and to assess the long-term impact of CDI on disease management and treatment escalation.
METHODS: We retrospectively analyzed 102 IBD patients hospitalized for disease flares at a single tertiary care center between January 2020 and September 2024. All patients underwent stool testing for enteric pathogens. Clinical, laboratory, and treatment data were collected at baseline and 12 months.
RESULTS: Gastrointestinal infections were detected in 19% of patients; CDI accounted for 58% of these. At 12 months after gastrointestinal infection, advanced therapy use was more frequent in gastrointestinal infection positive (GI+) patients (63% vs. 43%; P = 0.04). CDI+ patients had a significant increase in biologic use over time. Gastrointestinal infection positivity was independently associated with biologic use at 12 months (odds ratio = 3.5, P = 0.02).
CONCLUSION: Recognizing gastrointestinal infection promptly and integrating infection history into therapeutic decision-making may improve patient outcomes by preventing severe disease progression and guiding timely escalation of therapy.
METHODS: We retrospectively analyzed 102 IBD patients hospitalized for disease flares at a single tertiary care center between January 2020 and September 2024. All patients underwent stool testing for enteric pathogens. Clinical, laboratory, and treatment data were collected at baseline and 12 months.
RESULTS: Gastrointestinal infections were detected in 19% of patients; CDI accounted for 58% of these. At 12 months after gastrointestinal infection, advanced therapy use was more frequent in gastrointestinal infection positive (GI+) patients (63% vs. 43%; P = 0.04). CDI+ patients had a significant increase in biologic use over time. Gastrointestinal infection positivity was independently associated with biologic use at 12 months (odds ratio = 3.5, P = 0.02).
CONCLUSION: Recognizing gastrointestinal infection promptly and integrating infection history into therapeutic decision-making may improve patient outcomes by preventing severe disease progression and guiding timely escalation of therapy.